Rab25 upregulation correlates with the proliferation, migration, and invasion of renal cell carcinoma

Rab31 promoted hepatocellular carcinoma (HCC) progression via inhibition of cell apoptosis induced by PI3K/AKT/Bcl-2/BAX pathway

“…A growing evidence demonstrated that several members of Rab family is involved in the progression of various cancers. Rab25 has been found to promote proliferation, migration, and invasion of renal cell carcinoma [16] and head and neck squamous cell carcinoma [17]. Rab24 was also found to be involved in cisplatin resistance in human epithelial ovarian cancer [18].…”

RIN1 promotes renal cell carcinoma malignancy by activating EGFR signaling through Rab25

“…Rab25 (Catx‐8, Rab11c) is a member of the Rab family that plays a key role in governing apical and late endosomal recycling routes . Increased Rab25 is associated with poor patient outcome in ccRCC, likely through effects on metastatic pathways . Mechanistically Rab25‐decorated vesicles transport integrins, PI3K and EGFR, facilitating aggressive tumor growth and metastasis.…”

“…Rab25 have been shown to play important roles in receptor recycling (including EGFR recycling) in kidney cells . By analyzing the transcriptional levels of 52 Rab GTPases in RCC tissues, Rab25 was the most significantly upregulated one . We have previously demonstrated Rab25 plays an oncogene role in urothelial carcinoma .…”

High expression of Rab25 contributes to malignant phenotypes and biochemical recurrence in patients with prostate cancer after radical prostatectomy

“…After that, accumulating studies have revealed the aberrant expression of Rab25 and its associations with development, progression and prognosis of numerous types of human cancers. For example, Cao et al [9] showed the overexpression of Rab25 protein in gastric cancer compared to adjacent normal gastric tissues by immunohistochemistry and Western blot, and also confirmed that it promoted the invasion and metastasis of gastric cancer; Mitra et al [15] substantiated a striking context dependent role of Rab25 in breast cancer where Rab25 may be amplified and enhanced aggressiveness in luminal B cancers while in claudin-low tumors, Rab25 may be lost implying possible anti-tumor functions; Zhang et al [12] indicated that Rab25 may promote metastasis of bladder cancer via inducing the epithelial-mesenchymal-transition process and activating Akt/GSK-3β/Snail signaling pathway; Li et al [13] revealed that high levels of Rab25 expression were correlated with renal cell carcinoma invasion classification, lymph-node metastasis and pathological stage; Liu et al [20] also identified Rab25 as a potential prognostic biomarker in clear cell renal cell carcinoma; Geng et al [25] found that Rab25 was overexpressed in human hepatocellular carcinoma and may contribute to cancer cell proliferation and invasion possibly through regulation of the Wnt signaling pathway; Ma et al [26] indicated that Rab25 expression was a potential prognostic index for advanced non-small cell lung cancer patients and its inhibition might improve chemosensitization in non-small cell lung cancer treatment. In contrast, the data of Te′llez-Gabriel et al [14] supported a tumor suppressor role for Rab25 in head and neck squamous cell carcinoma and its potential use to identify locally advanced patients with a high probability of survival after genotoxic treatment; Goldenring et al [16] reported that colorectal adenocarcinomas with low Rab25 correlated with shorter patient survival.…”

“…Accumulating studies have shown the aberrant expression of Rab25 in various human cancers and also indicated its associations with carcinogenesis, cancer progression and patients’ outcome [8–16]. Rab25 is frequently amplified in head and neck tumors [8], gastric cancer [9], ovarian cancer [10], cervical cancer [11], bladder cancer [12] and renal cancer [13], but is downregulated in esophageal cancer [14], breast cancer [15] and colorectal cancer [16]. Functionally, it acts either as an oncogene or a tumor suppressor with a cancer-specific manner.…”